Results 251 to 260 of about 1,197,904 (347)

Clinical progress note: Hepatitis A virus. [PDF]

J Hosp Med
McCluskey JM, Bockrath RA, Jhaveri R.
europepmc   +1 more source

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

International Journal of Cancer, EarlyView.
What's New? Circulating nuclear DNA (cir‐nDNA)‐based assessment of minimal residual disease (MRD) offers powerful post‐surgery prognostic insight for stage III colon cancer (CC). Sparse knowledge of post‐surgical variations and origins in cir‐nDNA, however, has limited its clinical application.
Andrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, Alexia Mirandola, Ekaterina Pisareva, Javier Gonzalo Ruiz, Marco Macagno, Nadia Saoudi Gonzalez, Evelyne Crapez, Marc Ychou, Ramon Salazar Soler, Elisabetta Fenocchio, Paula X. Fernandez Calotti, Thibault Mazard, Cristina Santos Vivas, Elena Elez, Federica Di Nicolantonio, Alain R. Thierry   +17 more
wiley   +1 more source

Hepatitis C Virus Treatment Outcomes Using a Family Medicine Interdisciplinary Team. [PDF]

Ann Fam Med
Hull M.
europepmc   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

International Journal of Cancer, EarlyView.
What's New? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt, Sami Kilpinen, Johanna Arola, Benjamin Z. Sundqvist, Tom Böhling, Leif C. Andersson, Harri Sihto   +6 more
wiley   +1 more source

Hepatitis A virus link to atopic disease

, 2003
J. McIntire, S. Umetsu, C. Macaubas, Elisabeth G. Hoyte, C. Cinnioğlu, L. Cavalli-Sforza, G. Barsh, J. Hallmayer, P. Underhill, N. Risch, G. Freeman, R. DeKruyff, D. Umetsu   +12 more
semanticscholar   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, EarlyView.
What's New? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

Hepatitis Delta Virus Infection: An Overview. [PDF]

Pathogens
Duque V, Duque D.
europepmc   +1 more source

External cephalic version outcomes with tocolysis and sedation: A 10‐year retrospective cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To evaluate the effectiveness and safety of external cephalic version (ECV) performed with tocolysis and sedation or spinal anesthesia, and to identify predictors of ECV success, complications, and delivery outcomes after successful ECV. Methods This 10‐year cohort study included 990 pregnant women with term non‐cephalic presentation
Javier Sánchez‐Romero, Rosa María Gallego‐Pozuelo, José Eliseo Blanco‐Carnero, Javier Herrera‐Giménez, Fernando Araico‐Rodríguez, Alberto Rafael Guijarro‐Campillo, Aníbal Nieto‐Díaz, Catalina de Paco‐Matallana   +7 more
wiley   +1 more source

Hepatitis B virus and hepatitis D virus co-infection complicated by autoimmune hepatitis: Two case reports. [PDF]

World J Clin Cases
Dou J, Zhao XY, Wang ZG, Ning ZH, Wang XZ, Guo F.   +5 more
europepmc   +1 more source

Retrospective Analysis of Blood Donor Deferral Reasons and Optimization Suggestions for Deferral Policies

iLABMED, EarlyView.
This retrospective study analyzes the deferral reasons for 148,282 blood donors during 2019–2023 (overall deferral rate: 12.37%), identifying primary deferral reasons (e.g., elevated ALT for temporary deferral at 51.33%, HBsAg positivity for permanent deferral at 4.12%).
Limei Feng, Li Liu, Rui Wang, Ting Zhang, Wei Guo, Yang Yu   +5 more
wiley   +1 more source